Skip to content
Menu

Aptevo Therapeutics Inc. APVO

Full chart Compare
Set alert

Price alert · APVO

All alert types
0.41 USD -0.03 (-7.20%)

Regular-session close

0.41 0.00 +0.10%

After hours · Nov 19, 7:48 PM ET

0.377 Day range 0.4623
0.377 52-week range 25.56
YTD
-95.61%
1 year
-98.12%

5D -0.3023 (-40.40%)

0.40000.50000.60000.7000ThuFriMonTueWed0.4460
Market cap
1.43M
EPS (ttm)
66.96
Shares out
500.33K
P/E ratio
0.01
Forward P/E
-0.83
YTD return
-95.61%
1-year return
-98.12%
50-day average
8.69
200-day average
31.59
Volume
544.48K
Avg volume
123.91K
Open
0.4508
Previous close
0.446
Day's range
0.377 – 0.4623
52-week range
0.377 – 25.56
Beta
5.07
Analysts
Buy
Price target
21.00 (+4973.7%)

Key statistics

Enterprise value
78.72M
Price / book
18.69
Free cash flow
-14.68M
Total cash
7.75M
Total debt
4.83M
Return on equity
-250.96%
Short % of float
7.60%

Fundamental scorecard

4 of 25 checks passed on APVO’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
APVO Revenue — quarterly 0
APVO Net income — quarterly -6.36M
APVO EPS — quarterly -5.31

Earnings

APVO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-20.65-17.39+3.26+15.79%
Aug 8, 2024Jun 1, 2024-69.93-60.51+9.42+13.47%
May 8, 2024Mar 1, 2024-510.87-360.51+150.36+29.43%
Apr 4, 2024Dec 1, 20230.00———
Nov 14, 2023Sep 1, 2023-1,149.21-798.06+351.15+30.56%
Aug 10, 2023Jun 1, 2023-1,787.65-1,963.23-175.58-9.82%

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on APVO — it syncs with the Stock Master app.

Insider holders

APVO insider holders
InsiderRelationLatest transactionDateShares held
ABDUN-NABI DANIEL JDirectorConversion of Exercise of derivative securityMay 30, 2024277
GRANT GRADY IIIDirectorConversion of Exercise of derivative securityMay 30, 2024198
HARSANYI ZSOLTDirectorConversion of Exercise of derivative securityMay 30, 2024280
KUNZ BARBARA LOPEZDirectorConversion of Exercise of derivative securityMay 30, 2024198
KWON SOYOUNGGeneral CounselConversion of Exercise of derivative securityAug 7, 2024801
LAMOTHE JEFFREY GChief Operating OfficerConversion of Exercise of derivative securityAug 7, 20241,166

Institution ownership

APVO institution ownership
Holder% heldSharesValueReported
Hudson Bay Capital Management Lp1.73%25,285122.38KSep 29, 2024
Citadel Advisors Llc0.21%3,01714.60KSep 29, 2024
Geode Capital Management, LLC0.08%1,1815.72KSep 29, 2024
Virtu Financial LLC0.08%1,1345.49KSep 29, 2024
Renaissance Technologies, LLC0.07%9894.79KSep 29, 2024
HRT Financial LP0.05%7603.68KSep 29, 2024

Fund ownership

APVO fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.08%1,1595.61KOct 30, 2024
Vanguard Extended Market Index Fund0.00%56271Sep 29, 2024
Legg Mason Global Asset Mgt Tr-Franklin U.S. Small Cap Equity Fd0.00%629Sep 29, 2024